corrigendum to: lack of association between transforming growth factor beta 1-509c/t and +915g/c polymorphisms and chronic hepatitis b in iranian patients [published in hepatitis monthly. 2014 april; 14(4): e13100]

Corrigendum to: Lack of Association Between Transforming Growth Factor Beta 1-509C/T and +915G/C Polymorphisms and Chronic Hepatitis B in Iranian Patients [Published in Hepatitis Monthly. 2014 May; 14 (5): e13100]

lack of association between transforming growth factor beta 1 -509c/t and +915g/c polymorphisms and chronic hepatitis b in iranian patients

objectives in this study, the association of tgf-β1 +915g/c and -509c/t gene polymorphisms with chronic hepatitis b was evaluated in iranian patients. materials and methods a population-based case–control study was conducted in taleghani hospital, tehran. a number of 220 patients with chronic hepatitis b and the same number of healthy control subjects were designated the case and the control gr...

Lack of Association Between Transforming Growth Factor Beta 1 -509C/T and +915G/C Polymorphisms and Chronic Hepatitis B in Iranian Patients

BACKGROUND Chronic hepatitis B is one of the world's major health concerns [corrected]. The etiological agent of this infection is hepatitis B virus (HBV), which can evade the immune system response. Transforming growth factor beta 1 (TGF-β1) can act against HBV by suppressing the viral replication. The TGF-β1 also plays an important role in preventing liver damage in chronically HBV infected p...

Investigation of Transforming Growth Factor-β1 Gene Polymorphisms Among Iranian Patients With Chronic Hepatitis C

BACKGROUND Chronic hepatitis C infection is caused by the hepatitis C virus (HCV), and its clinical complications include liver cirrhosis, liver failure, and hepatocellular carcinoma.Transforming growth factor-β1 (TGF-β1) is an important cytokine in cell growthand differentiation, angiogenesis, extracellular matrix formation, immune responseregulation, and cancer development and progression. ...

investigation of transforming growth factor-β1 gene polymorphisms among iranian patients with chronic hepatitis c

YMDD and FLLAQ Mutations in Chronic Hepatitis B Patients

Abstract Background and Objective: Lamivudine is the first orally available drug approved for treatment of chronic hepatitis B. Mutations at the YMDD and FLLAQ motifs in the domains of HBV polymerase gene contribute resistance to lamivudine. This study was aimed to determine the rate of YMDD and FLLAQ mutants in hepatitis B patients in Golestan Province, Iran. Material and methods: In this cros...